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ABSTRACT 
Regorafenib is a multi-kinase inhibitor orally administered to colorectal cancer patients, and 
is known to often exhibit dermal toxicity. The purpose of the present study was to clarify 
possible involvement of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) 
in the dermal accumulation of regorafenib and its active metabolites M-2 and M-5. 
Following intravenous administration in Abcb1a/1b/bcrp-/- (TKO) and wild-type (WT) mice, 
delayed plasma clearance of M-2 and M-5, but not regorafenib, was observed in TKO mice 
compared to WT mice. Elacridar, an inhibitor of both transporters, also caused delayed 
clearance of M-2 and M-5, suggesting that these transporters are involved in their 
elimination. Skin-to-plasma concentration ratios of regorafenib, M-2, and M-5 were 
significantly higher in TKO mice than in WT mice. Elacridar increased skin-to-plasma and 
epidermis-to-plasma concentration ratios of regorafenib. Basal-to-apical transport of M-2 
and M-5 was observed in LLC-PK1-Pgp and MDCKII/BCRP/PDZK1 cells, which was 
inhibited by elacridar and the BCRP inhibitor Ko143, respectively. The present findings thus 
indicate that P-gp and BCRP are involved in the accumulation of regorafenib and its active 
metabolites in the skin, by affecting either their systemic exposure or their plasma 
distribution in the circulating blood. 
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Abbreviations: ABCB1, ATP binding cassette subfamily B member 1; ABCG2, ATP 
binding cassette subfamily G member 2; BCRP, breast cancer resistance protein; CRC, 
colorectal cancer; CYP3A4, cytochrome P450 3A4; GIST, gastrointestinal stromal 
tumor; HFS, hand-foot syndrome; LC-MS/MS, high-performance liquid 
chromatography/tandem mass spectrometry; LLC-PK1-Pgp, LLC-PK1 cells stably 
expressing human P-gp; M-2, regorafenib (pyridine)-N-oxide; M-5, N-desmethyl 
regorafenib (pyridine)-N-oxide; MDCKII/BCRP/PDZK1, MDCKII cells stably 
expressing both BCRP and PDZK1; Papp, apparent permeability coefficient; P-gp, 
P-glycoprotein   
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Introduction 
 Regorafenib is an oral, small-molecule multi-kinase inhibitor that blocks the 
activity of various protein kinases involved in the regulation of tumor angiogenesis 
(vascular endothelial growth factor receptor-1, -2, and -3 and TIE2), oncogenesis (KIT, 
RET, RAF1, and wild-type and V600E mutant BRAF), and the tumor 
microenvironment (platelet derived growth factor receptor and fibroblast growth factor 
receptor).1 Regorafenib showed significant survival benefits in patients with metastatic 
colorectal cancer (CRC) who had progressed on all available standard therapies or were 
unable to tolerate standard therapies.2 In addition, oral regorafenib significantly 
improved progression-free survival of patients with metastatic gastrointestinal stromal 
tumors (GIST), compared to placebo.3 Thus, treatment with regorafenib can benefit 
these patients, and it has been approved for the treatment of metastatic CRC and GIST.  
 Despite the significant survival advantages observed in regorafenib treatment, 
the drug induces characteristic adverse skin reactions such as hand-foot syndrome 
(HFS), at a high frequency.4,5 In a meta-analysis of regorafenib trials, HFS was reported 
to occur at a rate of 61% overall and 20% at grade 3.5 Such adverse skin reactions 
sometimes cause dose reduction and/or treatment discontinuation. Therefore, it is 
clinically important to clarify possible mechanisms for such dermal toxicity. 
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Regorafenib is metabolized by cytochrome P450 3A4 (CYP3A4) primarily in the liver 
to form two major active metabolites, regorafenib (pyridine)-N-oxide (M-2), and 
N-desmethyl regorafenib (pyridine)-N-oxide (M-5),6,7 which possess pharmacological 
activities similar to those of regorafenib. Therefore, accumulation of not only 
regorafenib but also M-2 and M-5 in the skin of hands and/or feet could be important in 
the induction of HFS. However, the tissue distribution mechanisms of regorafenib and 
its active metabolites remain unclear.   
 Systemic exposure and tissue distribution of therapeutic agents are generally 
determined by the action of drug-metabolizing enzymes and transporters. In addition to 
CYP3A4, regorafenib and M-2 are metabolized by UDP-glucuronosyltransferase 1A9 
to form inactive glucuronides M-7 and M-8, which are predominantly excreted in 
urine.6,7 However, regorafenib and its active metabolites formed by CYP3A4 are mainly 
excreted in feces.6,7 Regorafenib is a substrate of the hepatic uptake transporter, organic 
anion transporting polypeptide 1B1, although detailed information on its role in vivo is 
not available.8 Regorafenib, M-2, and M-5 have also been reported to be substrates of 
human ATP-binding cassette transporters, ABCB1 (P-glycoprotein, P-gp), and ABCG2 
(breast cancer resistance protein, BCRP).7,9 Kort et al.9 proposed that these transporters 
are primarily involved in accumulation of regorafenib and M-2 in the brain using triple 
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knockout (Abcb1a/1b/bcrp-/-, TKO) mice lacking Abcb1a, Abcb1b, and bcrp genes.9 On 
the contrary, oral bioavailability of regorafenib was minimally affected by gene 
knockout of these transporters9, suggesting their minimal involvement in the 
gastrointestinal absorption of regorafenib. No information is available on the effect of 
these transporters on the accumulation of regorafenib or its active metabolites in the 
skin, despite the impact of dermal toxicity in the clinical application of this drug. 
 Functional expression of both P-gp and BCRP in the skin has been partially 
characterized. Gene expression of both transporters was detected in the skin of humans 
and mice.10,11 According to immunohistochemical analyses, both transporters are 
localized to capillary endothelial cells in both species.12,13 Distribution of intravenously 
injected substrates to skin is restricted by these transporters.12 In addition, both P-gp and 
BCRP are localized to the basal layer of epidermis keratinocytes.12,13 Interestingly, these 
transporters have also been proposed to be involved in absorption of their substrates 
from skin to circulation after topical application, and localization of these transporters in 
both keratinocytes and endothelial cells may lead to such bidirectional transport.12,14 
However, information on the possible role of these transporters in the skin is still quite 
limited. 
 Based on this background, possible involvement of P-gp and BCRP in dermal 
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accumulation of regorafenib and its active metabolites was examined in the present 
study. For this purpose, regorafenib, M-2, or M-5 was intravenously administered to 
both TKO and WT mice to study the role of these transporters, avoiding the effects of 
gastrointestinal absorption. Sugiyama and coworkers15 have provided scientific basis for 
an apparent “synergistic” effect of these two transporters on drug permeation through 
the blood-brain barrier: loss of these two transporters leads to a far more drastic change 
in brain distribution compared with loss of a single transporter.16 In the present study, 
therefore, we used TKO mice to clearly detect the roles of these transporters in dermal 
distribution. Effect of elacridar, an inhibitor of P-gp and to a lesser extent, BCRP, was 
also examined to investigate the role of these transporters in the distribution of 
regorafenib and its metabolites. In vitro transcellular transport studies were also 
performed to examine possible transport of M-2 and M-5 by these transporters, because 
such information is lacking and only information on regorafenib transport is available.9 
The in vitro and in vivo results of the present study may help to elucidate the 
pharmacokinetic factors associated with regorafenib-induced skin toxicity, benefiting 
ongoing clinical pharmacology studies in CRC patients treated with regorafenib, 
including ongoing ones in our research group. 
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Materials and Methods 
Materials 
Regorafenib, M-2, M-5, and elacridar were purchased from Toronto Research 
Chemicals (Ontario, Canada). Ko143 was from Sigma-Aldrich (St. Louis, MO). 
Imatinib mesylate was from Focus Biomolecules (Plymouth Meeting, PA). Afatinib, 
bortezomib, cabozantinib, carfilzomib, dabrafenib, dacomitinib, dasatinib, lapatinib, 
lenvatinib, pazopanib, ponatinib, ruxolitinib, tofacitinib, trametinib, vandetanib and 
vemurafenib were from AdooQ Bioscience (Irvine, CA). Sorafenib was from LKT 
Laboratories Inc. (St. Paul, MN). Sunitinib was from Synkinase Pty Ltd (San Diego, 
CA). Crizotinib was from LC Laboratories Inc. (Woburn, MA). Gefitinib and erlotinib 
were from Cayman Chemical Company (Ann Arbor, MI). Nilotinib was from 
Chemscene, LLC (Monmouth Junction, NJ). All other chemicals and reagents were of 
analytical grade and were obtained from commercial sources. 
 
Animals 
Seven- to 9-week-old male TKO and FVB (WT) mice were purchased from 
Taconic (Hudson, NY) and CLEA Japan (Tokyo, Japan), respectively. ICR mice 
obtained from Japan SLC (Hamamatsu, Japan) were also used in the inhibition studies. 
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Mice were housed in a temperature- and light-controlled environment with standard 
food and tap water provided ad libitum. Animal experiments were carried out in 
accordance with the Guide for the Care and Use of Laboratory Animals of Kanazawa 
University. 
 
Pharmacokinetic Studies in Mice 
Mice were fasted overnight with free access to water and anesthetized with an 
intraperitoneal injection of pentobarbital. Regorafenib, M-2 and M-5 were dissolved in 
a mixture of saline, tween 80, and dimethyl sulfoxide (98:1:1). Elacridar was dissolved 
in a mixture of saline, dimethyl sulfoxide, and propylene glycol (1:2:2). Regorafenib (1 
mg/3.3 mL/kg body weight), M-2, or M-5 (160 μg/3.3 mL/kg body weight) was 
administered into the jugular vein. Elacridar (10 mg/2 mL/kg body weight) or vehicle 
alone was administered into the jugular vein of ICR mice 30 min before the injection of 
regorafenib, M-2, or M-5. At various intervals after the administration, blood samples 
were collected through the tail vein. All blood samples were immediately centrifuged to 
obtain plasma. After the last blood sampling, mice were euthanized, and abdominal skin, 
brain, liver, kidney, and lung were collected. In some experiments, the skin was divided 
into epidermis and dermis as described previously.12 To collect bile samples, the 
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gallbladder was cannulated with polyethylene tubing (SP10, Natsume Seisakusho Co., 
Ltd., Tokyo, Japan), and only bile samples were collected from mice. Cassette dosing of 
24 molecularly targeted small molecules was performed by injection of the following 
three mixtures into the jugular vein: (i) a mixture of crizotinib (297 µg/kg), erlotinib 
(130 µg/kg), gefitinib (148 µg/kg), imatinib (163 µg/kg), pazopanib (28.9 µg/kg), 
regorafenib (319 µg/kg), sorafenib (153 µg/kg) and sunitinib (132 µg/kg); (ii) a mixture 
of dabrafenib (171 µg/kg), dacomitinib (155 µg/kg), dasatinib (161 µg/kg), lenvatinib 
(141 µg/kg), nilotinib (175 µg/kg), pazopanib (28.9 µg/kg), ponatinib (176 µg/kg), 
regorafenib (159 µg/kg) trametinib (203 µg/kg), and vandetanib (157 µg/kg); (iii) a 
mixture of afatinib (160 µg/kg), bortezomib (127 µg/kg), cabozantinib (166 µg/kg), 
carfilzomib (238 µg/kg), lapatinib (192 µg/kg), pazopanib (28.9 µg/kg), regorafenib 
(159 µg/kg), ruxolitinib (101 µg/kg), tofacitinib (266 µg/kg) and vemurafenib (162 
µg/kg). These mixtures were dissolved in a mixture of saline, tween 80 and dimethyl 
sulfoxide (88:2:10). At 60 min after the injection, plasma, brain, and abdominal skin 
were collected. All biological samples were stored at -80 oC until drug quantification. 
 
Transport studies in cell lines transfected with P-gp or BCRP cDNA 
MDCKII cells stably expressing both BCRP and PDZK1 
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(MDCKII/BCRP/PDZK1) were previously established and grown as described 
previously.17 LLC-PK1 cells stably expressing human P-gp (LLC-PK1-Pgp) were 
supplied from GenoMembrane Co., Ltd. (Yokohama, Japan) and were grown as 
described previously.18 Cells were seeded in Transwell polycarbonate inserts (3 μm pore 
size, 12 mm diameter; Corning, Corning, NY) at a density of 3 x 105 cells/well. After 3 
days of culture, the cell monolayers were washed twice with transport buffer (125 mM 
NaCl, 4.8 mM KCl, 5.6 mM D-glucose,1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, and 25 mM HEPES, pH 7.4). After pre-incubation for 30 min with or without 
inhibitors, the medium was removed, and pre-warmed transport buffer containing 
regorafenib, M-2, or M5 with or without inhibitors was added to the basal or apical 
chamber. In the inhibition study, M-2 or M-5 was added to the basal or apical chamber, 
whereas regorafenib was added to both sides (0, 1, and 10 µM for LLC-PK1-Pgp cells 
and 0, 0.1, 1, and 10 µM for MDCKII/BCRP/PDZK1 cells). At the designated times, a 
100 μL aliquot was sampled from the opposite side and replaced with an equal volume 
of prewarmed fresh buffer. The medium samples were stored at -80 oC until drug 
quantitation. The efflux ratio was calculated as the ratio of the apparent permeability 
coefficient (Papp) in the basal-to-apical direction to that in the apical-to-basal direction, 
where Papp was calculated as the slope of the regression line in the transport-time profile 
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of the drug divided by the product of initial drug concentration in the donor chamber 
and the cell monolayer surface area (1.1 cm2). 
 
Measurement of drug concentration 
Aliquots of plasma and medium samples were mixed with 15 and 6 volumes 
(v/v), respectively, of methanol with internal standard (sorafenib). Brain, liver, kidney, 
and lung tissue samples were homogenized in 4 volumes (w/v) of methanol with 
internal standard, and skin samples were homogenized in 12 volumes (w/v) of the 
solvent. The mixtures were vortexed, centrifuged (21,500 g, 10 min, 4 °C) twice, and 
the supernatants subjected to high-performance liquid chromatography/tandem mass 
spectrometry (LC-MS/MS). Quantification of all drugs was performed using a triple 
quadrupole mass spectrometer with electrospray ionization (LCMS-8040; Shimadzu, 
Kyoto, Japan) coupled to a liquid chromatography system (Nexera, Shimadzu). 
Chromatography was performed by means of gradient elution (flow rate 0.4 mL/min) as 
follows: 0–0.5 min, 95% A/5% B; 0.5–1.5 min, 95% A/5% B to 35%A/65% B; 1.5–5.5 
min, 35% A/65% B to 30%A/70% B; 5.5–6.0 min, 30% A/70% B to 5%A/95% B; 6.0–
7.0 min, 5% A/95% B; 7.0–7.1 min, 5% A/95% B to 95% A/5% B (A, water containing 
0.1% formic acid and 5 mM ammonium acetate; B, methanol containing 0.1% formic 
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acid and 5 mM ammonium acetate) on a Cosmosil 2.5C18-MS-II packed column (2.5 
μm particle size, 2.0 mm I.D. x 100 mm; Nacalai Tesque, Kyoto, Japan) at 50 °C. 
Multiple reaction monitoring in positive ion mode was set at 483.00–269.95 for 
regorafenib, 499.00–201.90 for M-2, 484.90–201.90 for M-5, 487.40–401.00 for 
afatinib, 368.20–227.10 for bortezomib, 502.10–323.05 for cabozantinib, 721.60–
100.05 for carfilzomib, 451.80–260.10 for crizotinib, 520.10–307.10 for dabrafenib, 
468.00–317.00 for dacomitinib, 489.30–402.15 for dasatinib, 394.10–278.05 for 
erlotinib, 447.40–128.10 for gefitinib, 494.20–394.05 for imatinib, 582.30–366.10 for 
lapatinib, 429.00–372.00 for lenvatinib, 531.00–490.00 for nilotinib, 438.10–357.10 for 
pazopanib, 533.20–260.05 for ponatinib, 306.90–265.80 for ruxolitinib, 465.00–270.10 
for sorafenib, 399.10–283.05 for sunitinib, 313.00–149.00 for tofacitinib, 616.30–




Total clearance (CLtot), distribution volume at steady state (Vdss), terminal 
elimination half-life (t1/2,z), and mean residence time (MRT) were estimated in each 
animal using moment analysis of the plasma concentration profiles obtained at 5, 15, 30, 
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60 , 120, 360, and 1440 min for regorafenib, and 1, 10, 60, 180 , 360, 480, and 600 min 
for M-2 and M-5. Tissue-to-plasma concentration (Kp) was obtained by dividing drug 
concentration in tissue by that in plasma, and the Kp ratio was further calculated by 
dividing Kp value in TKO mice by that in WT mice.  
 
Statistical Analysis 
All values are presented as mean ± S.E.M. The statistical significance of 
differences was determined using Student’s t-test. Differences with a P-value of less 
than 0.05 were considered to be statistically significant. 
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Results 
Roles of P-gp and BCRP in systemic exposure and dermal distribution of 
regorafenib and its active metabolites, M-2 and M-5 
 Regorafenib, M-2, and M-5 were separately injected intravenously in both 
TKO and WT mice, and their pharmacokinetics examined to clarify the possible role of 
P-gp and BCRP in their systemic exposure. The plasma concentration profile of 
intravenous regorafenib in TKO mice showed a slight initial decrease but was almost 
similar to that in WT mice (Fig. 1A). The plasma concentration of regorafenib in WT 
mice, but not TKO mice, showed a transient peak approximately 4 h after 
administration (Fig. 1A). However, the plasma concentration profiles of M-2 and M-5 
were significantly higher in TKO mice than in WT mice (Fig. 1B, 1C). Pharmacokinetic 
parameters were calculated based on the plasma concentration profiles (Table 1). The 
CLtot values of M-2 and M-5 were higher than that of their parent compound in WT 
mice (Table 1). The CLtot, t1/2,z and MRT values of M-2 and M-5 were significantly 
lower in TKO mice than in WT mice (Table 1), indicating higher systemic exposure of 
the active metabolites but not the parent compound, in TKO mice compared to WT 
mice. 
 Concentrations of regorafenib and its active metabolites in each organ were 
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next examined after intravenous administration of each compound. Skin concentrations 
of regorafenib, M-2, and M-5 were significantly higher in TKO mice than in WT mice 
(Fig. 2). A similar trend was observed in both brain and lung (Fig. 2). A difference in 
M-5 between the two strains was observed in all organs examined (Fig. 2). Tissue 
distribution was examined by calculating Kp values (Supplementary Fig. 1). The Kp 
values of regorafenib, M-2, and M-5 in skin and brain of TKO mice were significantly 
higher than those in WT mice (Supplementary Fig. 1), suggesting the roles of P-gp 
and/or BCRP in distribution of regorafenib and its active metabolites to these organs. 
The difference in brain distribution of regorafenib and M-2 between TKO and WT mice 
was consistent with a previous report by Kort et al.,9 although their data were obtained 
after oral administration of only regorafenib. 
     
Effect of elacridar on systemic exposure and dermal accumulation of regorafenib 
and its active metabolites 
 To further confirm the roles of P-gp and BCRP in systemic exposure and 
dermal distribution of regorafenib and its active metabolites, elacridar, an inhibitor of 
P-gp and BCRP was co-administered with regorafenib, M-2, or M-5 in WT mice, and 
their plasma and tissue concentrations measured. The plasma concentration profile of 
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regorafenib with elacridar co-administration showed a slight decrease 1 h post 
administration, but was similar to that with vehicle co-administration (Fig. 3A). On the 
other hand, plasma concentrations of M-2 and M-5 were significantly higher in 
elacridar-treated mice than in control (Fig. 3B, 3C), especially in the terminal phase. 
The effect of elacridar on M-5 seemed to be more prominent (Fig. 3B, 3C).  
 The concentration of regorafenib and its active metabolites in each organ was 
next examined after intravenous administration of each compound with or without 
elacridar. Skin and brain concentrations of regorafenib, M-2, and M-5 were significantly 
higher in elacridar-treated mice than in control (Fig. 4). In this experiment, the skin was 
divided into epidermis and dermis. Regorafenib concentrations in both epidermis and 
dermis were significantly higher with elacridar than without elacridar (Fig. 4D, 4E). The 
Kp value of regorafenib in skin and brain, but not liver, in elacridar-treated mice was 
significantly higher than that in control mice (Supplementary Fig. 2), whereas the Kp 
values of M-2 and M-5 in elacridar-treated mice were not significantly different from 
those in control mice (Supplementary Fig. 2). Kp values of regorafenib in both 
epidermis and dermis were also significantly higher in elacridar-treated mice than in 
control mice (Supplementary Fig. 2D, 2E). 
 
  19 
Biliary excretion of M-5  
After intravenous injection of M-5 in WT mice, approximately 65% of the dose 
was recovered in bile during the first 6 h, but only a small percentage was recovered in 
the bile of TKO mice (Fig. 5).  
 
Interaction of regorafenib and its active metabolites with P-gp and BCRP 
In vitro transcellular transport studies were next performed to examine possible 
interaction of regorafenib and its active metabolites with human P-gp and BCRP. In 
LLC-PK1-Pgp cells, basal-to-apical transport of regorafenib, M-2, and M-5 was higher 
than the reverse transport, the efflux ratio of M-5 being highest (Fig. 6A, 6C, 6E). Such 
directional transport was diminished in the presence of elacridar, the efflux ratios being 
reduced almost to 1 (Fig. 6A, 6C, 6E). In MDCKII/BCRP/PDZK1 cells, similar 
directional transport was observed for each compound, and the efflux ratios were 
reduced in the presence of the BCRP inhibitor Ko143 (Fig. 6B, 6D, 6F). According to 
package insert information, regorafenib is as a potent inhibitor of BCRP and a modest 
inhibitor of P-gp in vitro (IC50 values for BCRP and P-gp are 50 nM and 2 µM, 
respectively),6 although no reports of such experimental data can be found. Therefore, 
the effect of regorafenib on directional transport of M-2 and M-5 was examined in both 
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cell lines, and it was found that efflux ratios of both M-2 and M-5 were decreased by 
regorafenib in a concentration-dependent manner (Fig. 6G, 6H). Since regorafenib 
concentration in the culture medium could decrease due to non-specific adsorption, it 
was directly measured by LC-MS/MS to account for any such variation. In 
MDCKII/BCRP/PDZK1 cells particularly, the ratios for M-2 and M-5 were almost 
completely decreased by regorafenib at ~50 nM (Fig. 6H).  
 
Correlation between distribution of molecularly targeted small molecules in skin 
and brain due to P-gp and BCRP 
The effect of gene knockout and elacridar on tissue concentration and Kp 
values of regorafenib and its active metabolites was similar in skin and brain (Figs. 2, 4, 
and Supplementary Figs. 1, 2), prompting us to perform similar studies using additional 
molecularly-targeted small molecules to verify similarity in their distribution profiles. 
Three mixtures of therapeutic agents, all of which included both regorafenib and 
pazopanib, were intravenously injected in both TKO and WT mice, and the Kp ratio, 
which in principle represents the contribution of transporter-mediated transport over 
passive transport,19 was obtained. Among the 24 compounds administered, plasma and 
skin levels in TKO and WT mice were detectable for 12 compounds, allowing 
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calculation of their Kp ratios. The skin Kp ratios were significantly correlated with the 
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Discussion 
 Regorafenib exhibits significant survival advantages in a set of cancer 
patients,2,3 but treatment frequently induces a characteristic HFS,4,5 which sometimes 
results in dose reduction and/or treatment discontinuation. Therefore, understanding of 
the mechanisms for accumulation of regorafenib and its active metabolites, M-2 and 
M-5, in the skin could clarify HFS risk factors to improve therapy. The present study 
has demonstrated, for the first time, that the transporters P-gp and BCRP are involved in 
accumulation of all of these compounds in the skin, by showing that (i) the disruption of 
Abcb1a, Abcb1b, and Bcrp genes in mice resulted in significantly higher concentrations 
of regorafenib, M-2, and M-5 in the skin (Fig. 2); (ii) treatment with elacridar in WT 
mice also led to an increase in dermal concentration of these compounds (Fig. 4); and 
(iii) directional transport of all these compounds was observed in both LLC-PK1-Pgp 
and MDCKII/BCRP/PDZK1 cells, but was diminished in the presence of elacridar and 
Ko143, respectively. According to the findings, these transporters could be involved in 
either systemic elimination or dermal distribution of these compounds. In the case of 
regorafenib, for example, dermal distribution, but not systemic elimination is primarily 
mediated by these transporters, since the plasma concentration profile after intravenous 
administration of regorafenib was similar in TKO and WT mice (Fig. 1A), whereas the 
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skin Kp value of regorafenib in TKO mice was significantly higher than that in WT 
mice (Supplementary Fig. 1A). In contrast, P-gp and BCRP may contribute to both 
systemic elimination and dermal distribution of M-2 and M-5, because their plasma 
concentration profiles and Kp ratios after intravenous administration in TKO mice were 
significantly higher than those in WT mice (Fig. 1B, 1C, Supplementary Fig. 1F, 1K). 
Possible functional compensation after genetic deletion of P-gp and BCRP should be 
considered in the pharmacokinetic analyses in TKO mice. In the present study, therefore, 
the direct effect of an inhibitor elacridar for P-gp and BCRP was also examined, and the 
inhibitory effect on tissue accumulation was also observed (Fig. 3, 4). Hashimoto et al.20 
examined gene expression of several efflux transporters in both TKO and WT mice, and 
found that mRNA expression of multidrug resistance associated protein (MRP) 1, 3, 4, 
and 5 was similar between TKO and WT mice, whereas that of MRP2 was not detected 
in either of the strains. On the other hand, Oatp1a4 protein expression in brain 
capillaries of TKO mice was approximately 2-fold lower than that of WT mice.21 
Although regorafenib was reported to be a substrate of human OATP1B1 in vitro,8 
influx transporter(s) involved in cellular uptake of M-2 or M-5 have not yet been 
identified. Influx transporter for regorafenib in mouse skin is also unknown. Further 
investigation of the uptake mechanism for regorafenib and its metabolites are needed. 
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The probable involvement of BCRP in accumulation of regorafenib and its 
metabolites in the skin is likely to prompt further pharmacogenomic studies, especially 
with regard to possible association between functional polymorphisms in its coding 
gene ABCG2 and dermal toxicity. One such known polymorphism is c.421C>A 
(p.Q141K, rs2231142), which is thought to affect amino acids in the ATP-binding 
domain of BCRP, leading to impaired BCRP activity in vitro.22 Mechanistic studies 
suggest that the polymorphism also alters transporter function by lowering its protein 
expression level through ubiquitin-mediated proteasomal and lysosomal degradation.22 
A compelling body of literature supports the clinical relevance of c.421C>A in human 
ABCG2 for multiple substrates, where a significant association of this polymorphism 
with the pharmacokinetics or pharmacodynamics of several drugs has been identified in 
genome-wide studies.23 In fact, a higher systemic exposure to tyrosine kinase inhibitors 
such as gefitinib, erlotinib, and sunitinib was observed in cancer patients with 
c.421C>A compared to those without the polymorphism.24 Similarly, higher systemic 
exposure and/or higher dermal distribution of regorafenib and its active metabolites may 
be expected in patients with the c.421C>A polymorphism, leading to dermal toxicity. 
The frequency of regorafenib-induced HFS of grade 3 or greater in Japanese cancer 
patients (28%) was higher than that in a non-Japanese, mostly caucasian population 
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(15%),25 which may be a reflection of the fact that the frequency of c.421C>A in Asians 
(30%) was higher than that in Caucasians (10%).22 Regarding the genetic 
polymorphisms in ABCB1 gene, the variants, 1236C>T (p.G412G, rs1128503), 
2677G>T/A (p.A893S/T, rs2032582) and 3435C>T (p.I1145I, rs1045642) occur at high 
allele frequencies and create a common haplotype. Therefore, they have been most 
widely studied. However, although these polymorphisms of the ABCB1 gene are 
sometimes associated with changes in drug disposition, drug response, and toxicity, the 
findings have been in part conflicting, and the clinical implications remain to be 
limited.26 Therefore, these variants in ABCB1 may not be associated with 
regorafenib-induced dermal toxicity. On the other hand, Zimmerman et al.27 have 
recently reported the existence of a skin transporter for another multi-kinase inhibitor 
sorafenib, implying possible involvement of multiple transport mechanisms for dermal 
distribution of regorafenib and its active metabolites. Further studies are warranted to 
elucidate all the mechanisms of their dermal distribution in humans.  
 It is also noteworthy that gene deletion of Abcb1a, Abcb1b and Abcg2 leads to 
a slight decrease in plasma concentration of regorafenib (Fig. 1A). A similar decrease in 
plasma regorafenib concentration was also observed when elacridar was 
co-administered (Fig. 3A), suggesting that this phenomenon is mediated by either P-gp 
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or BCRP. Therefore, loss of function of these transporters may also result in a decrease, 
but not increase, in systemic exposure of the parent compound. Although the exact 
reasons for such change in systemic exposure of the parent compound are unknown, one 
of the possible explanations would be the increase in distribution of regorafenib to 
peripheral organs by the loss of those efflux transporters. This reasoning is supported by 
the higher volume of distribution at steady state (Vdss) value in TKO mice compared 
with WT mice (Table 1). Although distribution to the liver was not affected by the gene 
deletion (Fig. 2C, Supplementary Fig. 2C), the distribution of regorafenib to the skin of 
TKO mice was higher than that in WT mice (Fig. 2A, Supplementary Fig. 2A). 
Therefore, it is likely that distribution to other large organs may also be hindered by 
these transporters. The other possible explanations would include the absence of 
enterohepatic recirculation of regorafenib in TKO mice. Plasma concentration of 
regorafenib was transiently increased for 1-4 h after intravenous administration in WT, 
but not TKO mice (Fig. 1A, 3A), suggesting enterohepatic recirculation of regorafenib, 
possibly mediated by P-gp and BCRP. Another possible explanation is that the loss of 
these transporters may increase regorafenib exposure in the liver, thereby promoting its 
metabolism to M-2 or other metabolites. This type of transporter-enzyme interplay has 
already been proposed by Lam et al.28, indicating that inhibition of efflux transporters 
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promotes enzymatic metabolism possibly due to the increase in available drug 
concentration in the liver. In the present study, however, hepatic concentration (Fig. 2C) 
as well as CLtot (Table 1) of regorafenib in TKO mice were similar to those in WT mice, 
suggesting that such transporter-enzyme interplay may not be supported by the present 
findings.  
In the present study, regorafenib at approximately 50 nM was found to almost 
completely inhibit the transcellular transport of M-2 and M-5 in 
MDCKII/BCRP/PDZK1 cells (Fig. 6H). Since the medium concentration of regorafenib 
was directly measured, this concentration range of regorafenib is unlikely to have been 
affected by loss of regorafenib due to nonspecific adsorption. The maximum plasma 
regorafenib concentration in cancer patients who received repeated oral doses of 
regorafenib was reported to be ~7.2 µM,29 and its unbound concentration was deduced 
to be 36 nM considering the unbound fraction of regorafenib in human plasma (0.005).7 
We have recently found CRC patients with 11 µM plasma regorafenib in our ongoing 
clinical study. Taking these considerations into account, inhibition of BCRP by 
regorafenib could be clinically relevant. The possible interaction of regorafenib and its 
active metabolites with BCRP (Fig. 6G, 6H) leads to the hypothesis that increase in 
regorafenib concentration leads to an increase in not only the synthesis of the active 
  28 
metabolites, but also inhibition of their efflux from skin or other organs. In particular, 
loss of P-gp and BCRP caused a drastic decrease in CLtot of M-5, compared with that of 
regorafenib and M-2 (Table 1). In vitro transcellular transport studies suggested that 
M-5 is highly transported by both P-gp and BCRP, as indicated by a higher efflux ratio 
compared with that of regorafenib and M-2 (Fig. 6). If we also consider that 
intravenously administered M-5 is largely excreted into the bile (Fig. 5), these 
transporters could be primarily involved in systemic elimination of M-5, which could be 
inhibited by a BCRP inhibitor such as regorafenib. Thus, the findings imply possible 
parent drug-metabolite interactions, which may lead to complex pharmacokinetics of 
regorafenib and its metabolites, to be clarified by further analyses in humans.  
In the present study, elimination phase of regorafenib in circulating plasma was 
almost unchanged in TKO and elacridar-treated mice, compared with WT mice (Figs 
1A, 3A). One of the possible explanations would be small contribution of P-gp and 
BCRP to overall elimination of regorafenib from systemic circulation. If efflux 
transporters expressed in the liver other than P-gp and BCRP play major roles in biliary 
excretion of regorafenib, its systemic elimination in TKO and elacridar-treated mice 
would be almost unchanged. However, no information is available on whether 
regorafenib is a substrate of other efflux transporters or not. Regorafenib is also 
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eliminated by the metabolism. Nevertheless, Kort et al.9 reported that plasma 
concentration-time profile of regorafenib in Cyp3a-/- mice was almost similar to that in 
WT mice, whereas that of M-2 in Cyp3a-/- mice was much lower than that in WT mice, 
suggesting that Cyp3a-medaited metabolism may not exhibit so much impact in 
systemic elimination of regorafenib. Another possible explanation would be the 
inhibition of P-gp and/or BCRP by regorafenib itself, as demonstrated in vitro in the 
present study (Fig. 6), resulting in minimal difference in biliary excretion of regorafenib 
between TKO and WT mice at the intravenous dose examined in Fig. 1. Actually, the 
hepatic concentration of regorafenib was approximately 2,000 ng/g liver (Figs. 2C, 4C), 
which corresponds to 4 µM if we assume that the specific gravity of the tissue is unity. 
Since unbound fraction in the liver is not available, if we further assume that the 
unbound fraction of regorafenib in the mouse liver is equal to that in human plasma 
(0.005),6,7 hepatic unbound concentration of regorafenib was estimated to be 
approximately 20 nM, which was not so much different from the concentration range at 
which regorafenib inhibits P-gp- and BCRP-mediated transport (Fig. 6G, 6H). This 
hypothesis may also explain minimal difference in both plasma (Figs. 1A, 3A) and 
hepatic (Figs. 2C, 4C) regorafenib concentrations between TKO/elacridar-treated and 
WT mice. 
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The higher Kp value of regorafenib in the skin of TKO and elacridar-treated 
mice compared with WT and vehicle-treated mice, respectively (Supplementary Figs. 1, 
2), suggested the possible role of P-gp and BCRP as efflux transport systems for this 
compound in the skin. Since these transporters are expressed on capillary endothelial 
cells in the skin of mice and humans,12,13 such efflux transport in the skin may be 
analogous to that in the blood-brain barrier, in which both P-gp and BCRP play 
fundamental roles. In fact, the consistent difference in Kp values of regorafenib and 
M-2 between TKO and WT mice, and elacridar- and vehicle-treated mice, was also 
observed in the brain (Supplementary Figs. 1, 2). In the present study, further studies 
were performed using drugs other than regorafenib, and Kp ratios in skin and brain were 
found to be correlated (Fig. 7), supporting similar roles of these transporters in both 
organs. However, endothelial cell-cell junctions in the skin may not be as tight as in the 
brain, leading to the speculation that the paracellular route, in addition to a transcellular 
one, may act in the dermal distribution of low molecular weight compounds. This may 
be supported by the present finding that the Kp ratios in skin were generally lower than 
those in the brain (Fig. 7). Nevertheless, a drastic increase in the concentration of 
regorafenib metabolites by loss of P-gp and BCRP (Figs. 2, 4) may still indicate the role 
of these transporters as a determining factor for drug accumulation in the skin. Since 
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treatment with regorafenib in patients induces adverse skin reactions such as HFS at a 
high frequency, these transporters may also be risk factors for the dermal toxicity. This 
hypothesis needs to be further evaluated in our ongoing clinical studies. In addition, 
these transporters are also localized on the basal layer of epidermis keratinocytes,12,13 
which include immature, but proliferative epithelial cells. BCRP is also expressed in 
both epidermal Langerhans cells and dermal interstitial dendritic cells, and is possibly 
involved in differentiation of myeloid dendritic cell progenitors to Langerhans cells in 
the skin.30 Thus, it is possible that the interaction of regorafenib and its active 
metabolites with BCRP in non-endothelial cells may also be associated with dermal 
events provoked by regorafenib. 
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Figure Legends 
Fig. 1. Systemic elimination of regorafenib, M-2, and M-5 after intravenous 
administration 
After intravenous administration of regorafenib (1 mg/kg body weight, A), M-2 (160 
µg/kg body weight, B), or M-5 (160 µg/kg body weight, C), the plasma concentration of 
each compound was measured in WT (closed circles) and TKO (open circles) mice. 
Each value represents the mean ± S.E.M. (n = 4-9, 3-7, and 4-8 in panels A, B, and C, 
respectively).  
*, Significant difference compared to WT mice (p<0.05). 
 
Fig. 2. Tissue concentration of regorafenib, M-2, and M-5 after intravenous 
administration 
After intravenous administration of regorafenib (1 mg/kg body weight), M-2 (160 µg/kg 
body weight), or M-5 (160 µg/kg body weight), the concentrations of regorafenib (A-E), 
M-2 (F-J), and M-5 (K-O) were measured at 6 h, 10 h and 10 h, respectively in WT 
(closed bars), and TKO (open bars) mice. Each value represents the mean ± S.E.M. (n = 
4-5, 4, and 4 in panels A-E, F-J, and K-O, respectively).  
*, Significant difference compared to WT mice (p<0.05). 
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Fig. 3. Effect of elacridar on systemic elimination of regorafenib, M-2, and M-5 
after intravenous administration 
At 30 min after intravenous administration of elacridar (10 mg/kg body weight, closed 
circles) or vehicle alone (open circles), regorafenib (1 mg/kg body weight, A), M-2 (160 
µg/kg body weight, B) or M-5 (160 µg/kg body weight, C) was also intravenously 
administered, and plasma concentration of each compound was measured in ICR mice. 
Each value represents the mean ± S.E.M. (n = 5).  
*, Significant difference compared to vehicle-treated mice (p<0.05). 
 
Fig. 4. Effect of elacridar on tissue concentration of regorafenib, M-2, and M-5 
after intravenous administration 
At 30 min after intravenous administration of elacridar (10 mg/kg body weight, closed 
bars) or vehicle alone (open bars), regorafenib (1 mg/kg body weight, panels A-E), M-2 
(160 µg/kg body weight, panels F-H) or M-5 (160 µg/kg body weight, panels I-K) was 
also intravenously administered, and tissue concentration of each compound was 
measured at 6 h after the injection in ICR mice. Each value represents the mean ± 
S.E.M. (n = 5).  
*, Significant difference compared to vehicle-treated mice (p<0.05). 
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Fig. 5. Biliary excretion profile of M-5 after its intravenous administration 
Cumulative biliary excretion of M-5 was determined in WT (closed circles) and TKO 
(open circles) mice. Each value represents the mean ± S.E.M. (n = 4-5). 
 
Fig. 6．Transcellular transport of regorafenib, M-2, and M-5, and inhibition of 
directional transport of M-2 and M-5 by regorafenib in LLC-PK1-Pgp and 
MDCKII/BCRP/PDZK1 cells.  
In panels A-F, 1 µM of regorafenib (A, B), M-2 (C, D), or M-5 (E, F) was applied to 
either the basal (circles) or the apical (diamonds) side in the presence (closed symbols) 
or absence (grey symbols) of elacridar (5 µM) or Ko143 (1 µM) in LLC-PK1-Pgp (A, C, 
E) or MDCKII/BCRP/PDZK1 (B, D, F) cells, respectively, and transcellular transport to 
the opposite side was measured. In panels G and H, similar studies of M-2 and M-5 (1 
µM each) were performed with regorafenib present on both sides in LLC-PK1-Pgp (G) 
or MDCKII/BCRP/PDZK1 (H) cells. The abscissa represents mean regorafenib 
concentration in culture medium at the end of experiments, measured by LC-MS/MS.  
 
Fig. 7．Correlation between Kp ratios of various molecularly-targeted small 
molecules in skin and brain 
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Three mixtures of 24 drugs were intravenously administered in TKO and WT mice, and 
plasma and tissue concentrations were measured at 60 min after the injection (see 
Methods for details). Data represent mean values of each drug (n = 3-5). 
 
